PureTech plans to take LYT-310 into the clinic, with the expectation that an oral capsule form of delivery could prove more effective than oil-based formulations.
The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientific’s Nantheia ATL5, a candidate for treating opioid use disorder.
Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.
Cure Pharma expands its DEA license to include authorization to manufacture both cannabis plant extracts and CBD within the scope of its patent portfolio.
Noramco partners with Nemus to produce an analogue of cannabidiol that possesses greater bioavailability, that could be used to treat diseases of the retina.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
GW Pharma has told investors its capacity is “more than sufficient” to meet launch requirements in Europe next year, where the firm’s CBD medicine Epidiolex is under review.
Lexaira Bioscience says its DehydraTECH platform has demonstrated significant improvements to the bioavailability of cannabinoids, and could be applied to other pharmaceuticals.
